Penumbra, Inc. — Third Quarter 2026 Earnings Summary

Penumbra, Inc. reported third-quarter 2026 revenue of $410.1 million, representing a 15.6% increase from the same period in 2025. Global thrombectomy revenue grew 18.1% to $279.2 million, while global embolization and access revenue rose 10.8% to $131.0 million. The company achieved a gross profit margin of 68.3% and reported net income of $42.3 million for the quarter. Due to the pending acquisition by Boston Scientific Corporation, Penumbra will not provide full-year 2026 financial guidance or host a conference call.